Skip to main content
Clinical Trials/NCT06543953
NCT06543953
Completed
Not Applicable

Remote Support for Cochlear Implant Recipients: Evaluation of the HearCare MED-EL App

MED-EL Elektromedizinische Geräte GesmbH3 sites in 1 country120 target enrollmentAugust 20, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hearing Loss, Sensorineural
Sponsor
MED-EL Elektromedizinische Geräte GesmbH
Enrollment
120
Locations
3
Primary Endpoint
Primary Endpoint to assess performance of the HearCare MED-EL App by installing a new audio processor configuration and performing a system check with the HearCare MED-EL App
Status
Completed
Last Updated
5 months ago

Overview

Brief Summary

This clinical investigation intends to assess safety and performance of the HearCare MED-EL App, a remote care option for recipients of MED-EL cochlear implants

Detailed Description

Remote care solutions can provide cochlear implant users a greater convenience, accessibility, and personalized care. These advantages stem from the ability to fine-tune and adjust their devices from the comfort of their own environments, without the need for frequent and time-consuming in-person clinic visits. Remote care allows clinicians to remotely assess data, provide guidance, and make necessary adjustments, all while minimizing the need for physical presence. This streamlined approach translates to increased capacity for serving a larger number of patients, ultimately leading to improved patient outcomes. The HearCare MED-EL App is a mobile smartphone application designed for recipients of at least one compatible MED-EL cochlear implant and respective audio processor. The app manages technical checks on compatible cochlear implants and audio processors, creates and utilizes backups of audio processor configurations, and performs updates of audio processor configurations by acting as an executive organ of the MAESTRO System Software. The app reduces face-to-face follow-up appointments of users/caregivers with hearing professionals while maintaining safe and ongoing care for all individuals. This clinical investigation aims to evaluate the HearCare MED-EL App regarding safety and performance.

Registry
clinicaltrials.gov
Start Date
August 20, 2024
End Date
November 26, 2025
Last Updated
5 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
MED-EL Elektromedizinische Geräte GesmbH
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \> 18 years
  • Implanted with at least one MED-EL Cochlea Implant (CI) for at least 3 months
  • Fitted with at least one audio processor compatible with the HearCare MED-EL App (i.e. SONNET 2, SONNET 2 EAS, RONDO 3 or newer)
  • Signed and dated Informed Consent Form (ICF) before the start of any study-specific procedure

Exclusion Criteria

  • Lack of compliance with any inclusion criteria
  • Implanted with C40X and C40C
  • Implanted with an Auditory Brainstem Implant (ABI) or Split electrode array
  • Anything that, in the opinion of the Investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study (e.g. psychological disorders, neurologic or motoric comorbidity that could restrict subjects from using the app)

Outcomes

Primary Outcomes

Primary Endpoint to assess performance of the HearCare MED-EL App by installing a new audio processor configuration and performing a system check with the HearCare MED-EL App

Time Frame: immediately after the intervention

The primary endpoint is success rate of the HearCare MED-EL app in percent for both the installation of new audio processor configurations and the detection of technical issues of audio processors or implants.

Secondary Outcomes

  • Product specific questionnaire (for users)(2 months after the intervention)
  • Speech test in quiet(immediately after the intervention)
  • Speech test in noise(immediately after the intervention)
  • Product specific questionnaire (for professionals)(through study completion, an average of 2 years)
  • Device parameters(immediately after the intervention)
  • Incidents of device related adverse events(through study completion, an average of 2 years)

Study Sites (3)

Loading locations...

Similar Trials